TARA · Protara Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $13.56M | - | $9.59M | $10.77M | $9.15M | - | $8.07M | $6.39M | $7.75M | - |
| SG&A | $6.07M | - | $5.17M | $5.82M | $4.98M | - | $4.26M | $4.27M | $4.10M | - |
| Total Operating Expenses | $19.63M | - | $14.76M | $16.59M | $14.12M | - | $12.33M | $10.66M | $11.85M | - |
| D&A | $90.0K | - | - | - | $83.0K | - | - | - | $83.0K | - |
| Operating Income | ($19.63M) | - | ($14.76M) | ($16.59M) | ($14.12M) | - | ($12.33M) | ($10.66M) | ($11.85M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($17.78M) | - | ($13.26M) | ($14.96M) | ($11.91M) | - | ($11.22M) | ($9.51M) | ($11.10M) | - |
| EPS - Basic | ($0.31) | - | ($0.31) | ($0.35) | ($0.29) | - | ($0.50) | ($0.45) | ($0.97) | - |
| EPS - Diluted | ($0.31) | - | ($0.31) | ($0.35) | ($0.29) | - | ($0.50) | ($0.45) | ($0.97) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.74M | $49.66M | $12.55M | $31.50M | $91.46M | $162.80M | $51.76M | $89.58M | $52.23M | $39.59M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.03M | $3.47M | $4.50M | $5.30M | $2.31M | $4.43M | $2.29M | $1.39M | $972.0K | $2.43M |
| Current Assets | $140.00M | $159.50M | $135.64M | $125.09M | $126.53M | $172.16M | $85.08M | $92.21M | $57.91M | $68.70M |
| Total Assets | $191.92M | $209.47M | $144.64M | $156.93M | $168.56M | $181.45M | $94.09M | $101.65M | $68.13M | $78.95M |
| Current Liabilities | $8.92M | $10.94M | $9.91M | $9.76M | $7.02M | $10.96M | $8.64M | $5.65M | $5.50M | $6.15M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $10.71M | $13.06M | $12.35M | $12.51M | $10.07M | $14.32M | $12.30M | $9.60M | $9.73M | $10.63M |
| Stockholders' Equity | $181.21M | $196.41M | $132.29M | $144.42M | $158.48M | $167.13M | $81.79M | $92.05M | $58.41M | $68.32M |
| Retained Earnings | ($320.20M) | ($302.42M) | ($285.11M) | ($271.85M) | ($256.89M) | ($244.98M) | ($232.21M) | ($220.99M) | ($211.48M) | ($200.38M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($21.34M) | - | - | - | ($14.71M) | - | - | - | ($10.38M) | - |
| Investing Cash Flow | ($14.72M) | - | - | - | ($58.35M) | - | - | - | $23.10M | - |
| Financing Cash Flow | $1.14M | - | - | - | $1.73M | - | - | - | ($76.0K) | - |
| CapEx | - | - | - | - | $44.0K | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | ($14.76M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 1.24 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.3% | - | -9.2% | -9.5% | -7.1% | - | -11.9% | -9.4% | -16.3% | - |
| Return on equity | -9.8% | - | -10.0% | -10.4% | -7.5% | - | -13.7% | -10.3% | -19.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 15.69 | 14.58 | 13.69 | 12.82 | 18.03 | 15.71 | 9.85 | 16.33 | 10.53 | 11.17 |
| Quick ratio | 15.69 | 14.58 | 13.69 | 12.82 | 18.03 | 15.71 | 9.85 | 16.33 | 10.53 | 11.17 |
| Cash ratio | 1.65 | 4.54 | 1.27 | 3.23 | 13.03 | 14.85 | 5.99 | 15.86 | 9.49 | 6.44 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.06 | 1.07 | 1.09 | 1.09 | 1.06 | 1.09 | 1.15 | 1.10 | 1.17 | 1.16 |
| Liabilities / Assets | 0.06 | 0.06 | 0.09 | 0.08 | 0.06 | 0.08 | 0.13 | 0.09 | 0.14 | 0.13 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.7x | - | 1.4x | 0.9x | 1.1x | - | 0.5x | 0.5x | 0.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -39.0% | - | -19.7% | -55.6% | -19.2% | - | -15.2% | 12.2% | -21.8% | - |
| Net income growth (YoY) | -49.3% | - | -18.2% | -57.3% | -7.4% | - | -13.8% | 15.8% | -22.7% | - |
| EPS growth (YoY) | -6.9% | - | 38.0% | 22.2% | 70.1% | - | 42.5% | 55.0% | -1.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 14.3% | 17.5% | 61.7% | 56.9% | 171.3% | 144.6% | 6.3% | 8.0% | -38.4% | -33.1% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Protara Therapeutics against the 5 most active filers in the same SIC group.